0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-12B & IL-12A

IL-12B & IL-12A

Brief Information

Name:Interleukin-12
Target Synonym:Interleukin-12
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IL2-H4210-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) stimulates the proliferation of PHA-P activated PBMC. The ED50 for this effect is 0.05 ng/mL (Routinely tested).

IL2-H4210-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

IL2-H4210-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Anti-IL23A & IL12B MAb (P40 domain) on Protein A Biosensor, can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 1.07 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL-12B & IL-12A Molecule Synonym Name

IL12,p70,Interleukin-12

IL-12B & IL-12A Molecule Background

Interleukin 12 (IL12) is also known as p70, and is an interleukin that is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation.IL12 is a heterodimeric cytokine, containing IL-12A (p35) and IL-12B (p40). IL-12 is involved in the differentiation of naive T cells into Th1 cells. It is known as a T cell-stimulating factor, which can stimulate the growth and function of T cells. It stimulates the production of IFN-γ and TNF-α from T cells and NK cells, and reduces IL-4 mediated suppression of IFN-γ. IL-12 plays an important role in the activities of natural killer cells and T lymphocytes. IL-12 also has anti-angiogenic activity, which means it can block the formation of new blood vessels.

IL-12B & IL-12A References

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular Details
Ustekinumab CNTO-1275; C-340; AVT-04 Approved Janssen Global Services Llc Stelara Mainland China Plaque psoriasis Janssen-Cilag International Nv 2009-01-15 Polymyositis; Solid tumours; Liver Cirrhosis, Biliary; Dermatomyositis; Inflammatory Bowel Diseases; Multiple Sclerosis; Lupus Erythematosus, Systemic; Psoriasis; Takayasu Arteritis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Dermatitis, Atopic Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Autoimmune Diseases Details
IL-12 gene therapy (Methodist Hospital) Phase 2 Clinical Methodist Hospital System Triple Negative Breast Neoplasms Details
Lisofylline BL-194; CT-1501R; A-802710 Phase 3 Clinical Cti Biopharma Corp Diabetes Mellitus, Type 1; Rejection of organ transplantation Details
NHS-IL-12 M-9241; MSB-0010360 Phase 2 Clinical Emd Serono Inc, Merck Serono, National Cancer Institute Neoplasms Details
INO-9012/Human papillomavirus vaccine (VGX Pharmaceuticals) INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 Phase 2 Clinical University Of Pennsylvania Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms Details
ONCR-177 ONCR-177 Phase 1 Clinical Oncorus Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
AK101 AK-101 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Interleukin-12 gene therapy (OncoSec Medical) pIL-12; DNA IL-12 Phase 2 Clinical Inovio Breast Neoplasms; Mycosis Fungoides; Melanoma; Carcinoma, Hepatocellular; Lymphoma, T-Cell, Cutaneous; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Ovarian Neoplasms; Hepatitis B; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms Details
Recombinant human anti-IL12 antibody (Bio-Thera Solutions) BAT-2206 Phase 3 Clinical Bio-Thera Solutions Ltd Autoimmune Diseases; Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab biosimilar(DM Bio) DA-3115; DMB-3115 Phase 3 Clinical Meiji Seika Pharma Co Ltd, Dong-A Pharmaceutical Co Ltd Psoriasis Details
Apilimod mesilate LAM-002; LAM-002A; STA-5326; STA-5326-mesylate Phase 2 Clinical Lam, Synta Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Psoriasis; Lymphoma, Non-Hodgkin; Crohn Disease; Immunologic Deficiency Syndromes Details
T3011疱疹病毒(深圳市亦诺微医药) Phase 2 Clinical Shenzhen Yinuowei Pharmaceutical Technology Co Ltd Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Ustekinumab Biosimilar (qyuns) QX-001-S; QX-001S Phase 3 Clinical Jiangsu Quanxin Biomedical Co Ltd Psoriasis; Plaque psoriasis Details
Ustekinumab biosimilar(Formycon) FYB-202 Phase 3 Clinical Formycon Immune System Diseases; Psoriasis Details
Ustekinumab biosimilar (BioFactura) BFI-751 Phase 1 Clinical BioFactura Australia Pty Ltd Psoriasis Details

This web search service is supported by Google Inc.

totop